摘要
目的:探讨血清人附睾蛋白4(HE4)和糖类抗原125(CA125)检测在卵巢癌、子宫内膜癌中的应用价值。方法:采用ELISA和化学发光微粒子免疫分析(CMIA)分别测定卵巢癌组、子宫内膜癌组、子宫肌瘤组和健康对照组的血清HE4和CA125,并对检验结果进行分析。结果:卵巢癌、子宫内膜癌的血清HE4、CA125联合检测的灵敏度明显高于单项检测,联合检测的特异性低于HE4单项检测,高于CA125单项检测。与术前比较,术后卵巢癌组HE4和CA125水平明显降低,两组差别具有统计学意义(P<0.01),但子宫内膜癌组HE4结果术前与术后水平比较差别无统计学意义(P>0.05)。结论:血清HE4和CA125两者联合检测可提高其在卵巢癌、子宫内膜癌中的临床应用价值,HE4可以作为卵巢癌术后随访的客观指标,但尚且不能作为子宫内膜癌术后随访的客观指标。
Objective ： To discuss the clinical value of serum human epididymis secretory protein 4 （ HE4 ） and CA125 in ovarian tumor and endometrial carcinoma. Methods： The levels of serum HE4 and CA125 were detected using ELISA and Chemical luminescence microparticle immune assay（CIMA） , then compared and analysed among ovarian tumor group, endometrial carcinoma group, leiomyoma of uterus group and control group. Results： The di- agnostic sensitivity of combined detection of HFA and CA125 in ovarian tumor group and endometrial carcinoma group were higher than respective detection. But the specificity of combined detection was lower than that of serum HFA,higher than that of CA125. Compared with pre- operation, the levels of HFA and CA125 in ovarian tumor group obviously decreased, the difference had statistical significance （P 〈 0.01 ） , but HE4 levels had no statistical difference between pre- operation and post- operation in endometrial carcinoma group （P 〉 0.05 ）. Conclusion： The combined detection of serum HFA and CA125 could improve their clinical value in ovarian tumor and endometri- al carcinoma, HFA is a useful index of ovarian tumor after surgical operation,but not the useful index of endometrial carcinoma after surgical operation.
出处
《中国卫生检验杂志》
北大核心
2013年第2期416-417,419,共3页
Chinese Journal of Health Laboratory Technology
